Advertisement
Advertisement
U.S. markets open in 7 hours 25 minutes
S&P Futures
3,858.50 +10.25 (+0.27%) Dow Futures
31,089.00 +76.00 (+0.25%) Nasdaq Futures
11,923.50 +43.25 (+0.36%) Russell 2000 Futures
1,734.60 +6.00 (+0.35%) Crude Oil
98.79 +0.26 (+0.26%) Gold
1,744.40 +7.90 (+0.45%)
Geron Corporation (GERN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 1.8100 |
| Open | 1.8000 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 2900 |
| Day's Range | 1.7700 - 1.8900 |
| 52 Week Range | 0.9900 - 1.8900 |
| Volume | |
| Avg. Volume | 2,603,541 |
| Market Cap | 702.051M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3590 |
| Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for GERN
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Geron CorporationTechnical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.RatingFair ValueEconomic Moat7 days agoArgus Research
- Zacks
Novartis (NVS) Announces Positive Data on Oncology Drug
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
- Business Wire
Geron Corporation Announces Expansion of Existing Loan Facility
FOSTER CITY, Calif., June 30, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.
- Zacks
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
